Ilumien Trials Support Optimal Coherence Tomography During PCI
This article was originally published in The Gray Sheet
St. Jude is touting data from two trials supporting optical coherence tomography as an important decision-making tool during percutaneous coronary intervention.
You may also be interested in...
Approvals and launches from Navidea Biopharmacueticals, Alphatec and more.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.